Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (AU:NEU)
:NEU
RESEARCH TOOLSreports
Holding AU:NEU?
Track your performance easily
NEU Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$10.90 - AU$24.25
Previous CloseN/A
Volume294.48K
Average Volume (3M)493.80K
Market Cap
AU$1.60B
Enterprise ValueAU$2.57B
Total Cash (Recent Filing)$5.05M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)13.3
Beta0.76
Next Earnings
Mar 04, 2025EPS Estimate
0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.92
Shares Outstanding130,065,670
10 Day Avg. Volume573,207
30 Day Avg. Volume493,802
Standard Deviation0.25
R-Squared0.22
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)123.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit176.55
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$18.37Price Target Upside66.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Neuren Pharmaceuticals Limited News
PremiumCompany Announcements
Neuren’s Trofinetide Moves Closer to European Approval for Rett Syndrome
PremiumCompany Announcements
Neuren Pharmaceuticals Announces Share Buy-Back Program
PremiumCompany Announcements
Neuren Pharmaceuticals Boosts Buy-Back Program
PremiumCompany Announcements
Neuren Pharmaceuticals Gains from Acadia’s $150M Voucher SalePremiumCompany Announcements
Neuren Pharmaceuticals Updates on Share Buy-Back Program
PremiumCompany Announcements
Neuren Pharmaceuticals’ Strategic Share Buy-Back UpdatePremiumCompany Announcements
Neuren Pharmaceuticals Boosts Shareholder Value with Buy-BackOptions Prices
Currently, No data available
---
Ownership Overview
0.02% Insiders
2.65% Mutual Funds
<0.01% Other Institutional Investors
94.33% Public Companies and
Individual Investors
NEU FAQ
What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest share price was AU$10.90 and its highest was AU$24.25 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Neuren Pharmaceuticals Limited’s market cap is AU$1.60B.
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s upcoming earnings report date is Mar 04, 2025 which is in 46 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Aug 27, 2024. The company reported AU$0.061 earnings per share for the quarter, missing the consensus estimate of AU$0.11 by -AU$0.049.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited does not currently pay dividends.
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is 0.98.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 130,065,670 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of AU$0.061 in its last earnings report, missing expectations of AU$0.11. Following the earnings report the stock price went down -2.603%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:NEU
---
Neuren Pharmaceuticals Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$18.37 (66.85% Upside)
AU$18.37 (66.85% Upside)
Blogger Sentiment
Bullish
AU:NEU Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.55%
12-Months-Change
Fundamentals
Return on Equity
73.89%
Trailing 12-Months
Asset Growth
134.72%
Trailing 12-Months
Company Description
Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.
---
NEU Company Deck
---
NEU Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Neuren's strong financial performance, significant cash growth, and successful collaboration with Acadia. Positive trial results for NNZ-2591 and an expanded global reach were significant achievements. However, challenges such as tax liabilities, exchange rate impacts, and share price volatility were noted. Overall, the positive aspects and strategic advancements overshadow the lowlights.Read More>---
NEU Stock 12 Month Forecast
Average Price Target
AU$18.37
▲(66.85% Upside)
Technical Analysis
Neuren Pharmaceuticals Limited
―
ACADIA Pharmaceuticals
―
ANI Pharmaceuticals
―
Axsome Therapeutics
―
Bioxcel Therapeutics
―
Cytokinetics
―
Insmed
―
Best Analysts Covering NEU
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+12.79%
reiterated a buy rating 2 months ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.79% per trade.
---